´ëÇÑ´ç´¢º´ÇÐȸ Á¦32Â÷ Ãá°èÇмú´ëȸ : 2019-05-09±³À°ÀÏÀÚ : 2019-05-09
±³À°Àå¼Ò : °æÁÖ È¹éÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
´ëÇÑ´ç´¢º´ÇÐȸ Á¦32Â÷ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 2 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 250,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ-ȸ¿ø 130,000¿ø/ºñȸ¿ø 200,000¿ø »çÀüµî·Ï: Àü°øÀÇ ¹× ±âŸ-ȸ¿ø 70,000¿ø/ºñȸ¿ø 90,000¿ø ÇöÀåµî·Ï: Àü¹®ÀÇ-ȸ¿ø 200,000¿ø/ºñȸ¿ø 250,000¿ø ÇöÀåµî·Ï: Àü°øÀÇ ¹× ±âŸ-ȸ¿ø 90,000¿ø/ºñȸ¿ø 110,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-09 °æÁÖÇÏÀÌÄÚ Room4 15:30~16:00 Should SGLT2 inhibitor be given first priority for patients with type 2 diabetes and ASCVD? ±è»ó¼ö(ºÎ»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 05-09 °æÁÖÇÏÀÌÄÚ Room4 16:00~16:30 SGL2 inhibitor in diabetic kidney disease ÇÑ»ó¿±(ÀÎÁ¦ÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 05-09 °æÁÖÇÏÀÌÄÚ Room4 16:30~17:00 Medical therapeutic strategies for cognitive dysfunction in patients with DM ¹Ú°æ¿ø(µ¿¾ÆÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 05-09 °æÁÖÇÏÀÌÄÚ Room4 17:00~17:30 ´ç´¢¹ß ȯÀÚÀÇ Ç÷·ù °³¼±À» À§ÇÑ ³»°úÀû Ä¡·á ¹ÚÀçÇü(°í·ÁÀÇ´ë ¼øȯ±â³»°ú)